Product Reviews
Take Action

Fight for Fair Finance

Tell the administration and Congress to stand up for the consumer watchdog that protects you from financial fraud and abuse.
Take Action
Why Do We Have Campaigns?
We're fighting to ensure you and your family can get a fair deal in the marketplace, especially on the choices that matter most: health care, privacy, automobiles, food, finances and more. Join our campaigns and together, we'll hold corporations and lawmakers accountable.

Milk thistle may be ineffective against hepatitis C

Consumer Reports News: November 22, 2011 10:38 AM

High oral doses of milk thistle, a botanical supplement used extensively by patients with chronic liver disease, is no more effective than placebo against chronic hepatitis C, according to preliminary findings of a clinical trial presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco last month.

Investigators at four U.S. clinical centers conducted the study involving 154 patients with hepatitis C who were previously unsuccessfully treated with interferon-based therapies and who had elevated serum liver enzymes that were above what’s considered the healthy range, according to an abstract of the study released at the AASLD meeting. The patients—mostly men, median age, 54—were randomly assigned to receive either a placebo or a standardized extract of milk thistle (also known as silymarin) at one of two higher-than-customary doses, three times a day for 24 weeks.

At the end of the study, investigators found no significant difference in liver enzyme levels across the three treatment groups, according to Michael Fried, M.D., a professor of Medicine and Director of Hepatology at the University of North Carolina. Of the138 patients who completed the treatments, only six (two in each treatment group) were found to have normalized or dramatically reduced liver enzyme levels, he reported. Silymarin at both higher doses was well tolerated, he said, with adverse effects that were comparable to placebo.

Bottom line: The findings, though notable, are preliminary since they have not yet been published in a peer-reviewed scientific journal.

Read more about hepatitis C treatment in our free Best Buy Drug Report.

Doug Podolsky

E-mail Newsletters

FREE e-mail Newsletters! Choose from cars, safety, health, and more!
Already signed-up?
Manage your newsletters here too.

Health News


Cars Build & Buy Car Buying Service
Save thousands off MSRP with upfront dealer pricing information and a transparent car buying experience.

See your savings


Mobile Get Ratings on the go and compare
while you shop

Learn more